# A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

> **NCT05615636** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- Hodgkin Lymphoma
- B-Cell Lymphoma
- Relapsed B-cell NHL

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Polatuzumab vedotin
- **DRUG:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05615636
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-28
- **Primary completion:** 2027-08-19
- **Final completion:** 2027-08-19
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05615636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05615636, "A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05615636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*